思珀生物有限公司成立于2021年，是一家专注于开发新型细胞产物治疗技术的创新生物技术公司。公司基于俄亥俄州立大学、斯坦福大学、MD 安德森癌症中心、纪念斯隆凯特琳、北京大学、安贞医院和阜外医院等海内外众多院校在内的合作伙伴的基础研究成果，孵化并开发出了自主知识产权的创新技术平台，投资方包括IDG资本、尚珹资本、LDVP和斯坦福大学等。公司在浙江海宁市的一期GMP标准生产设施约2000平米，目前已基本完成建设。
公司的联合创始人兼CEO，Andrew Lee拥有斯坦福大学的医学博士学位，发表了 50 多篇关于细胞和基因治疗的同行评审期刊论文。他同时也是一家医疗创新加速器公司（目前拥有450家以上的投资组合公司和超过4亿美元的风险基金）的创始人。
Spot Biotechnology Ltd., founded in 2021, is an innovative biotechnology company focuses Ｏn the development of novel cellular product therapy. The company has incubated and developed an innovative technology platform with its own intellectual property based Ｏn the fundamental research from the partners including Ohio State University, Stanford University, MD Anderson Cancer Center, Memorial Sloan Kettering, Peking University, Anzhen Hospital and Fuwai Hospital, etc. The company’s investors including IDG Capital, Shang Include Capital, LDVP and Stanford University. And the first stage of GMP Facility in Haining, Zhejiang province, approximately 2,000 square metres, is currently constructing and almost being completed.
CEO and Co-Founder, Andrew Lee, MD/PhD received his MD/PhD from Stanford University and has published over 50 peer-reviewed journal papers Ｏn cell and gene therapy. He is also the founder of a medical innovation accelerator company (500 portfolio companies and $400 million in venture funds).
浙公网安备 33048102000507号
